Literature DB >> 18849973

Induction of pluripotent stem cells from primary human fibroblasts with only Oct4 and Sox2.

Danwei Huangfu1, Kenji Osafune, René Maehr, Wenjun Guo, Astrid Eijkelenboom, Shuibing Chen, Whitney Muhlestein, Douglas A Melton.   

Abstract

Ectopic expression of defined sets of genetic factors can reprogram somatic cells to induced pluripotent stem (iPS) cells that closely resemble embryonic stem (ES) cells. The low efficiency with which iPS cells are derived hinders studies on the molecular mechanism of reprogramming, and integration of viral transgenes, in particular the oncogenes c-Myc and Klf4, may handicap this method for human therapeutic applications. Here we report that valproic acid (VPA), a histone deacetylase inhibitor, enables reprogramming of primary human fibroblasts with only two factors, Oct4 and Sox2, without the need for the oncogenes c-Myc or Klf4. The two factor-induced human iPS cells resemble human ES cells in pluripotency, global gene expression profiles and epigenetic states. These results support the possibility of reprogramming through purely chemical means, which would make therapeutic use of reprogrammed cells safer and more practical.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18849973     DOI: 10.1038/nbt.1502

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN: 1087-0156            Impact factor:   54.908


  525 in total

Review 1.  Pluripotency of human embryonic and induced pluripotent stem cells for cardiac and vascular regeneration.

Authors:  Kenneth R Boheler
Journal:  Thromb Haemost       Date:  2010-05-10       Impact factor: 5.249

Review 2.  Generation of pluripotent stem cells without the use of genetic material.

Authors:  Akon Higuchi; Qing-Dong Ling; S Suresh Kumar; Murugan A Munusamy; Abdullah A Alarfaj; Yung Chang; Shih-Hsuan Kao; Ke-Chen Lin; Han-Chow Wang; Akihiro Umezawa
Journal:  Lab Invest       Date:  2014-11-03       Impact factor: 5.662

Review 3.  From microRNAs to targets: pathway discovery in cell fate transitions.

Authors:  Deepa Subramanyam; Robert Blelloch
Journal:  Curr Opin Genet Dev       Date:  2011-06-01       Impact factor: 5.578

Review 4.  Using human pluripotent stem cells to untangle neurodegenerative disease mechanisms.

Authors:  Brigitte Malgrange; Laurence Borgs; Benjamin Grobarczyk; Audrey Purnelle; Patricia Ernst; Gustave Moonen; Laurent Nguyen
Journal:  Cell Mol Life Sci       Date:  2010-10-26       Impact factor: 9.261

Review 5.  Mechanism and methods to induce pluripotency.

Authors:  Peizhe Wang; Jie Na
Journal:  Protein Cell       Date:  2011-11-06       Impact factor: 14.870

6.  Expression of a2, a5 and a6 subunits of integrin in de-differentiated NIH3T3 cells by cell-free extract of embryonic stem cells.

Authors:  Zohreh Mostafavi-Pour; Sarva Keihani; Tahereh Talaei-Khozani; Pooneh Mokaram; Majid Fardaei; Leili Rohani; Saeedeh Ebadat; Ahmadreza Sardarian
Journal:  Mol Biol Rep       Date:  2012-07       Impact factor: 2.316

Review 7.  Epigenetic protein families: a new frontier for drug discovery.

Authors:  Cheryl H Arrowsmith; Chas Bountra; Paul V Fish; Kevin Lee; Matthieu Schapira
Journal:  Nat Rev Drug Discov       Date:  2012-04-13       Impact factor: 84.694

Review 8.  A case of cellular alchemy: lineage reprogramming and its potential in regenerative medicine.

Authors:  Grace E Asuelime; Yanhong Shi
Journal:  J Mol Cell Biol       Date:  2012-02-27       Impact factor: 6.216

9.  Critical regulation of miR-200/ZEB2 pathway in Oct4/Sox2-induced mesenchymal-to-epithelial transition and induced pluripotent stem cell generation.

Authors:  Guiying Wang; Xudong Guo; Wujun Hong; Qidong Liu; Tingyi Wei; Chenqi Lu; Longfei Gao; Dan Ye; Yi Zhou; Jie Chen; Jianmin Wang; Minjuan Wu; Houqi Liu; Jiuhong Kang
Journal:  Proc Natl Acad Sci U S A       Date:  2013-02-05       Impact factor: 11.205

Review 10.  Translating induced pluripotent stem cells from bench to bedside: application to retinal diseases.

Authors:  Alona O Cramer; Robert E MacLaren
Journal:  Curr Gene Ther       Date:  2013-04       Impact factor: 4.391

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.